[TSX] New Drug APP13007 Receives TFDA Approval

1. Date of event: 115/06/01. 2. Drug name: APP13007 (BYQLOVI Ophthalmic Suspension 0.05%). 3. Purpose: Treatment of pain and inflammation after ophthalmic surgery. 4. Development stage: N/A. 5. Current status: Approved by the Ministry of Health and Welfare. Accumulated R&D costs are not disclosed for commercial strategy reasons. 6. Next stage: N/A. 7. Market status: With the aging population and the prevalence of 3C products, cataract surgeries in Taiwan are increasing, exceeding 380,000 cases in 2023. Significant market potential is expected. 8. Other: None.